

UC San Diego

UC San Diego Previously Published Works

Title

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets

Permalink

<https://escholarship.org/uc/item/1hq456d2>

Journal

Molecular Oncology, 17(2)

ISSN

1574-7891

Authors

Viteri, Santiago
Minchom, Anna
Bazhenova, Lyudmila
[et al.](#)

Publication Date

2023-02-01

DOI

10.1002/1878-0261.13327

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

SHORT REPORT

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets

Santiago Viteri¹, Anna Minchom², Lyudmila Bazhenova³, Sai-Hong Ignatius Ou⁴, Joshua M. Baum^{5,*}, Scott A. Shell⁶, Michael Schaffer⁷, Junchen Gu⁷, Jennifer B. Rose⁷, Joshua C. Curtin⁷, Parthiv Mahadevia⁷ and Nicolas Girard⁸

1 UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, Spain

2 Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK

3 University of California San Diego, CA, USA

4 Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA

5 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

6 Guardant Health, Redwood City, CA, USA

7 Janssen R&D, Spring House, PA, USA

8 Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France

Keywords

EGFR; Exon 20 insertion mutations; NGS; NSCLC; PCR

Correspondence

S. Viteri, UOMI Cancer Center, Clínica Mi Tres Torres, Calle del Doctor Roux, 76, 08017 Barcelona, Spain
Tel: +34 93 546 0135
E-mail: sviteri@uomi.es

Present address

*Janssen R&D, Spring House, PA, USA

(Received 26 January 2022, revised 24 August 2022, accepted 20 October 2022, available online 28 November 2022)

doi:10.1002/1878-0261.13327

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for $\leq 12\%$ of all EGFR-mutant nonsmall cell lung cancers. We analysed real-world datasets to determine the frequency of ex20ins variants, and the ability of polymerase chain reaction (PCR) and next-generation sequencing (NGS) to identify them. Three real-world United States NGS databases were used: GENIE, FoundationInsights, and GuardantINFORM. Mutation profiles consistent with in-frame EGFR ex20ins were summarized. GENIE, FoundationInsights, and GuardantINFORM datasets identified 180, 627, and 627 patients with EGFR ex20ins respectively. The most frequent insertion region of exon 20 was the near loop ($\sim 70\%$), followed by the far loop ($\sim 30\%$) and the helical ($\sim 3\text{--}6\%$) regions. GENIE, FoundationInsights, and GuardantINFORM datasets identified 41, 102, and 96 unique variants respectively. An analysis of variants projected that $\sim 50\%$ of EGFR ex20ins identified by NGS would have been missed by PCR-based assays. Given the breadth of EGFR ex20ins identified in the real-world US datasets, the ability of PCR to identify these mutations is limited. NGS platforms are more appropriate to identify patients likely to benefit from EGFR ex20ins-targeted therapies.

1. Introduction

Mutations in the epidermal growth factor receptor (EGFR) are a key oncogenic driver in nonsmall cell lung cancer (NSCLC). The common mutations, exon 19 deletions and L858R substitution in exon 21, are

detected in 85–90% of all EGFR-mutant (EGFRm) NSCLCs [1]. The third most common type of EGFRm NSCLC is comprised of exon 20 insertion mutations (ex20ins), which are characterized by in-frame insertions or duplications typically clustered within or after the C-helix in the EGFR kinase domain [1]. The

Abbreviations

AA, amino acid; EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor-mutant; ex20ins, exon 20 insertion mutation; GENIE, Genomics Evidence Neoplasia Information Exchange; NGS, next-generation sequencing; NSCLC, nonsmall cell lung cancer; ORR, overall response rate; PCR, polymerase chain reaction; TKI, tyrosine kinase inhibitor.

reported frequency of EGFRm NSCLCs harbouring ex20ins is between 1% and 12% [2]. This broad range likely reflects the molecular heterogeneity of EGFR ex20ins and the limitations of available molecular assays to identify them [3].

Unlike common mutations, EGFR ex20ins are less sensitive to EGFR tyrosine kinase inhibitors (TKI) because the insertions create steric hindrance at the TKI-binding site [4]. The reported overall response rate (ORR) to approved EGFR TKIs is between 0% and 28% compared with response rates of 60–80% in patients with the common mutations [1,5]. Further, two real-world studies found overall survival was significantly lower (by ~10 months) for patients with ex20ins compared with those who have common EGFR mutations (16.2 versus 25.5 months [6] and 24.3 versus 35.4 months [7]). However, the Y764insFQEA variant has shown sensitivity to EGFR TKIs, suggesting that differential response to TKI treatment may be associated with the type and site of ex20ins [3,5]. Additionally, rates of sensitizing EGFR ex20ins vary geographically [8]; however, studies have found antitumour activity across ex20ins sites with amivantamab [9] and similar ORRs to mobocertinib in the near and far loops of exon 20 [10].

Investigational therapies for the treatment of EGFR ex20ins NSCLC are in development [5]. Amivantamab, an EGFR-MET bispecific antibody, and mobocertinib, an ex20ins-specific TKI, were recently approved by the FDA (and also the EMA for amivantamab) for the treatment of patients with EGFR ex20ins NSCLC, as detected by an FDA-approved test, whose disease progressed on or following platinum-based chemotherapy [9–12]. Therefore, the identification of tumours bearing EGFR ex20ins is important in guiding treatment decisions, and universal molecular testing should be able to accurately and comprehensively detect the wide range of variants that have been identified thus far. Real-time polymerase chain reaction (PCR) and next-generation sequencing (NGS) are two molecular methods commonly used to identify mutations in the EGFR gene [13,14]. The commercially available PCR-based assays detect ‘hot spot’ mutations and are designed to identify only a subset of known ex20ins. In contrast, NGS has the ability to detect multiple types of genetic mutations over a specified region, including any new mutations not identified previously [13,14], and is therefore expected to provide more complete coverage of EGFR ex20ins than PCR-based assays. The use of NGS has also steadily increased over the past decade [13], and the updated guidelines from the IASLC support the use of sequential or concurrent NGS tissue and liquid biopsy analyses [15]. In

this report, three real-world US NGS genomic databases were analysed to determine the frequency of EGFR ex20ins and to compare the ability of PCR versus NGS-based testing methods to identify these mutations.

2. Materials and methods

2.1. US genomic NGS databases

The American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) database is a public registry of real-world NGS genomic data collected from participating cancer centres [16]. In this analysis, NGS data extracted from the GENIE database, version 8.5, were limited to the 13 participating US institutions covering a total of 80 015 patients. DNA sequencing of tumour biopsy samples occurred between 2012 and 2019.

The FoundationInsights (Foundation Medicine, Cambridge, MA, USA) real-world US NGS database, version MI20200428, based on the FoundationCore knowledgebase of patient genomic profiles, spans over 150 cancer types. At the time of analysis (data cut-off of 28 April 2020), the database contained information for 315 688 samples from tumour biopsies.

The GuardantINFORM database contains real-world US NGS data collected from Guardant360 CDx liquid biopsy tests from over 174 087 patients (Guardant Health, Inc., Redwood City, CA, USA). The database query covered 1 February 2015 through 30 June 2021.

Given the limited scope of this study, information, such as demographics, clinical staging, treatments, and outcome variables, was not available. Only certain demographics (e.g. age, race, and gender) could be obtained from the GENIE database.

2.2. Data analysis

Exon 20 of the EGFR gene encompasses nucleotides that translate to amino acid (AA) positions 762–823. Mutation profiles from all three real-world datasets were evaluated for alterations (duplications and deletion/insertion) consistent with in-frame ex20ins of the EGFR gene. Ex20ins were summarized based on the resulting AA changes and were aggregated into frequencies per alteration. Coverage of ex20ins from commercially available PCR-based assays, Therascreen EGFR RGQ PCR Kit version 2 (Qiagen, Hilden, Germany) and cobas EGFR v.2 (Roche, Basel, Switzerland) were obtained from their instructions for use (Table S1). In

3. Results

To determine the real-world frequency of EGFR ex20ins, we analysed data from three NGS genomic datasets that included patients with NSCLC: GENIE ($N = 12\,497$), FoundationInsights ($N = 56\,382$), and GuardantINFORM ($N = 71\,191$). Among patients with NSCLC, EGFRm lung adenocarcinoma was diagnosed in 24% (GENIE), 23% (FoundationInsights), and 18% (GuardantINFORM) of patients (Fig. 1). Of note, the percentage of patients with EGFRm NSCLC from the FoundationInsights and GuardantINFORM databases reflect the ordering patterns of physicians and are not intended to represent the expected frequency of these patients in an unbiased US-based patient population. Among the 9673 patients with NSCLC adenocarcinomas in the GENIE database, the median age was 67 years old, most patients were female (60%) and the majority were White (77%), followed by African American/Black (7.6%) and Asian (6.9%). Demographics were not included from FoundationInsights and GuardantINFORM for this study.

The GENIE, FoundationInsights, and GuardantINFORM datasets identified 180, 627, and 627 patients with EGFR ex20ins, respectively, which accounted for ~ 7–8% of all EGFRm lung adenocarcinomas (Fig. 1). Across all three datasets, ~ 70% of EGFR ex20ins were found in the near loop region (AA 767–772), ~ 30% in the far loop region (AA 773–775), and ~ 3–6% in the

helical region (AA 762–766). The most frequent sites of insertion identified in all three datasets were located at AA 769 (21.1–25.4%), AA 770 (28.9–35.0%), and AA 773 (22.0–26.1%; Fig. 2).

The molecular heterogeneity of EGFR ex20ins was evident, with 41, 102, and 96 unique variants identified from the GENIE, FoundationInsights, and GuardantINFORM datasets respectively (Tables S1–S3). If the coverage for EGFR ex20ins from commercial PCR-based assays is applied to the GENIE dataset, only 89 of the 180 patients identified by NGS would have been identified, thereby missing 50.6% of all cases (Fig. 3A). In the FoundationInsights dataset, commercial PCR-based assays would have identified only 305 of the 627 patients identified by NGS, missing 51.4% of all EGFR ex20ins cases (Fig. 3B). Similar findings were observed with the GuardantINFORM dataset, where PCR-based assays would only have identified 313 of the 627 patients with EGFR ex20ins, missing 50.0% of patients (Fig. 3C).

Across all three datasets, only 23 EGFR ex20ins variants were found, underscoring the diversity of this class of mutations. Variants that were found exclusively in each dataset accounted for 24% (10/41) of the GENIE dataset, 50% (51/102) of the FoundationInsights dataset, and 47% (45/96) of the GuardantINFORM dataset (Tables S2–S4), suggesting a considerable degree of genomic heterogeneity among real-world US NGS databases.




Fig. 1. Patient selection across three real-world US databases. NGS data were extracted from the GENIE, FoundationInsights, and GuardantINFORM databases to identify patients with lung adenocarcinoma who harboured ex20ins. Data from the GENIE database were limited to those from participating US institutions. EGFR, epidermal growth factor receptor; ex20ins, exon 20 insertion mutation; NSCLC, nonsmall cell lung cancer.




Fig. 2. Frequency by site of insertion in exon 20 of the EGFR. The distribution of ex20ins by site of AA insertion from the GENIE (green; $N = 180$), FoundationInsights (blue; $N = 627$) and GuardantINFORM (orange; $N = 627$) datasets. Percentages are calculated using number of patients with EGFR ex20ins lung adenocarcinoma as the denominator. EGFR, epidermal growth factor receptor; ex20ins, exon 20 insertion mutation.

4. Discussion

In this real-world analysis using three US NGS genomic datasets, EGFR ex20ins variants account for ~1% of all NSCLC cases in each of the three databases. The estimated frequency of ex20ins was ~7–8% of all EGFRm lung adenocarcinomas, which is consistent with the range (up to 12%) reported in the literature from other US-based databases [13] and globally [2,17–20]. The near loop was the most frequent insertion region of EGFR ex20ins, where ~70% of all insertions were found. Insertions in the helical region, where sensitivity to EGFR TKIs has been reported [3,5], were uncommon. Importantly, the frequency of EGFR ex20ins observed in datasets that utilize NGS on tumour biopsies (GENIE and FoundationInsights) was generally consistent with that observed using liquid biopsies (GuardantINFORM), suggesting that both testing methods could accurately identify the diverse range of these mutations.

Over 80 distinct EGFR ex20ins variants have been identified [2]. This result is consistent with our study, where a large number of unique EGFR ex20ins variants were identified from the real-world NGS datasets, ranging from 41 variants in the GENIE dataset to 102 in the FoundationInsights dataset. Twenty-three EGFR ex20ins variants, which included those most frequently observed, were common to all three datasets. The genomic heterogeneity and breadth of

EGFR ex20ins identified in these real-world datasets emphasize the need for an accurate and comprehensive method to detect these mutations.

Although PCR-based assays have a quicker turnaround time, they have limited capacity for assessing multiple genes and variant types [14]. Real-world, retrospective studies have shown higher rates of detection of EGFR ex20ins with NGS compared with PCR [21] and similarly have suggested a high rate of missed EGFR ex20ins mutations with PCR testing versus NGS [22]. In this analysis, of the EGFR ex20ins variants identified in real-world NGS databases, commercial PCR-based assays would have detected only four of the variants, missing ~50% of all cases; however, in this population of patients, there are now two commercially available NGS tests (Oncomine Dx Target Test and Guardant360 CDx) approved as companion diagnostics for amivantamab and mobocertinib. Given the limited capacity of PCR-based assays to detect multiple genes and variants, sequential testing may be needed to cover the full range of potential biomarkers. This additional workflow would lead to increased costs, require larger tumour samples, and delay time to treatment [14,23]. In contrast, NGS offers comprehensive testing, with the ability to detect all relevant biomarkers (and yet-to-be-identified mutations) in a single test, either in tissue or liquid biopsies. This can reduce the need for re-biopsy, decrease the time to obtain test results, and




Fig. 3. EGFR ex20ins variants identified from the (A) GENIE ($N = 180$), (B) FoundationInsights ($N = 627$), and (C) GuardantINFORM ($N = 627$) datasets. Ex20ins variants identified in two patients or more are included in the bar chart. Ex20ins variants identified in only one patient and not detected by commercial PCR-based assays are listed in the box (inset). Red bars denote ex20ins variants that would not have been detected using commercial PCR-based assays. EGFR, epidermal growth factor receptor; ex20ins, exon 20 insertion mutation; PCR, polymerase chain reaction.

potentially provide cost savings by negating the need for sequential single-gene tests [23]. It should be noted that there are also limitations to NGS, such as difficulty interpreting novel variants, which may require the implementation of molecular tumour boards, lack of knowledge of the appropriate number of genes to be screened, and how to handle discordancy between commercially available tests run in parallel [24], the latter of which is not an unexpected entity as a recent review on liquid biopsies had also found poor concordance in ctDNA of prostate cancer samples between multiple assays [25].

The results of our study should be interpreted within its limitations. Potential confounders were not assessed due to the lack of demographic information excluded from all three databases.

5. Conclusions

In this analysis, the real-world US frequency of ex20ins was ~7–8% of all EGFRm lung adenocarcinomas. With up to 102 unique variants identified, the ability of PCR-based assays to comprehensively identify patients with these mutations is limited. The identification of all EGFR ex20ins variants will be important when implementing dedicated targeted therapies in the first-line setting. With several investigational therapies in development and the recent approval of amivantamab and mobocertinib, identifying patients who harbour these mutations with NGS-based testing methods will be important to ensure appropriate patient access to new targeted therapies.

Acknowledgements

The authors would like to acknowledge the American Association for Cancer Research and its financial and material support in the development of the AACR Project GENIE registry, as well as members of the consortium for their commitment to data sharing. Interpretations are the responsibility of study authors. This study was funded by Janssen Global Services, LLC, which had a role in the study design, analysis, and writing of the report and the decision to submit the article for publication. Writing assistance was provided by Tracy T. Cao, PhD (Janssen Global Services) and the study was funded by Janssen Global Services, LLC.

Conflict of interest

SV reports consulting and/or advising for AbbVie, Bristol Myers Squibb, Roche, Takeda, AstraZeneca,

and MSD; speakers bureau fees from Bristol Myers Squibb, MSD, Roche, and AstraZeneca; and travel expenses from Roche, OSE Pharma, Bristol Myers Squibb, Merck, Merck Serono, Puma Biotechnology, and Janssen Cilag. **AM** reports teaching and/or serving on an advisory board for Chugai, Janssen, Merck, Novartis, Faron, and Bayer; and expenses from LOXO and Amgen. **LB** reports consultative services for Daiichi Sankyo, Boehringer Ingelheim, Janssen, Bristol Myers Squibb, Merck, Novartis, and Regeneron; and research funding from BeyondSpring. **S-HIO** reports stock ownership of Turning Point Therapeutics, and Elevation; speaker honoraria from Merck, Roche/Genentech, AstraZeneca, Takeda/ARIAD, and Pfizer; and advisory fees from Roche/Genentech, AstraZeneca, Takeda/ARIAD, Pfizer, Foundation Medicine, Spectrum, X-Coverly, Janssen/Johnson & Johnson, and Daiichi Sankyo. **JMB** is a current employee of Janssen R&D and reports previous research/grant support from Merck, Clovis, Carevive Systems, Novartis, Bayer, Janssen, AstraZeneca, Takeda, and Carisma Therapeutics, and consultative services for Clovis, Bristol Myers Squibb, AstraZeneca, Celgene, Boehringer Ingelheim, Janssen, Merck, Guardant Health, Genentech, Takeda, Ayala, Regeneron, Inivata, and Novartis. **SAS** is an employee of Guardant Health. **JG**, **JBR**, **JCC**, and **PM** are employees of Janssen R&D, and own stock and/or stock options in Johnson & Johnson. **MS** is a former employee of Janssen R&D and own stock and/or stock options in Johnson & Johnson. **NG** reports research/grant support from MS, AstraZeneca, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, MSD, Novartis, Pfizer, Sivan, and Trizell, and consultative services for Bristol Myers Squibb, AstraZeneca, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi, and Sivan. A family member is an employee of AstraZeneca.

Author contributions

SV, AM, LB, S-HIO, JMB, MS, JG, JBR, JCC, PM, and NG contributed to conceptualization of study. MS, JG, and SAS contributed to data curation. MS and JG contributed to formal analysis and methodology. All authors contributed to writing and reviewing of the manuscript.

Peer review

The peer review history for this article is available at <https://publons.com/publon/10.1002/1878-0261.13327>.

Data accessibility

The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at <https://www.janssen.com/clinical-trials/transparency>. Data from the AACR Project GENIE are publicly available. Data from Foundation Medicine and Guardant were used under license for the current study and are not publicly available. Other researchers should contact Foundation Medicine and Guardant Health.

References

- 1 Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. *Signal Transduct Target Ther*. 2019;4:5. <https://doi.org/10.1038/s41392-019-0038-9>
- 2 Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. *PLoS ONE*. 2021;16:e0247620. <https://doi.org/10.1371/journal.pone.0247620>
- 3 Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. *Mol Cancer Ther*. 2013;12:220–9. <https://doi.org/10.1158/1535-7163.MCT-12-0620>
- 4 Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. *Nat Med*. 2018;24:638–46. <https://doi.org/10.1038/s41591-018-0007-9>
- 5 Remon J, Hendriks LEL, Cardona AF, Besse B. EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins. *Cancer Treat Rev*. 2020;90:102105. <https://doi.org/10.1016/j.ctrv.2020.102105>
- 6 Bazhenova L, Minchom A, Viteri S, Bauml JM, Ou SI, Gadgeel SM, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. *Lung Cancer*. 2021;162:154–61. <https://doi.org/10.1016/j.lungcan.2021.10.020>
- 7 Chouaid C, Filleron T, Debievre D, Perol M, Girard N, Dansin E, et al. A real-world study of patients with advanced non-squamous non-small cell lung cancer with EGFR exon 20 insertion: clinical characteristics and outcomes. *Target Oncol*. 2021;16:801–11. <https://doi.org/10.1007/s11523-021-00848-9>
- 8 Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. *Nat Rev Clin Oncol*. 2022;19:51–69. <https://doi.org/10.1038/s41571-021-00558-1>
- 9 Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. *J Clin Oncol*. 2021;39:3391–402. <https://doi.org/10.1200/JCO.21.00662>
- 10 Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. *JAMA Oncol*. 2021;7:e214761. <https://doi.org/10.1001/jamaoncol.2021.4761>
- 11 RYBREVANT. RYBREVANT (amivantamab-vmjw) injection, for intravenous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2021.
- 12 Takeda Pharmaceuticals America. EXKIVITY (mobocertinib): highlights of prescribing information. Lexington, MA: Takeda Pharmaceuticals America, Inc; 2021.
- 13 Lin HM, Yin Y, Crossland V, Wu Y, Ou SI. EGFR testing patterns and detection of EGFR exon 20 insertions in the United States. *JTO Clin Res Rep*. 2022;3:100285. <https://doi.org/10.1016/j.jtocrr.2022.100285>
- 14 Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. *Am Soc Clin Oncol Educ Book*. 2019;39:531–42. https://doi.org/10.1200/EDBK_237863
- 15 Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. *J Thorac Oncol*. 2021;16:1647–62. <https://doi.org/10.1016/j.jtho.2021.06.017>
- 16 AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. *Cancer Discov*. 2017;7:818–31. <https://doi.org/10.1158/2159-8290.Cd-17-0151>
- 17 Geng D, Guo Q, Huang S, Zhang H, Guo S, Li X. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer. *Clin Transl Oncol*. 2022;24:379–87. <https://doi.org/10.1007/s12094-021-02701-x>
- 18 John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn MJ. Uncommon EGFR mutations in non-small-cell lung cancer: a systematic literature review of prevalence and clinical outcomes. *Cancer Epidemiol*. 2022;76:102080. <https://doi.org/10.1016/j.canep.2021.102080>
- 19 Koopman B, Cajiao Garcia BN, Kuijpers C, Damhuis RAM, van der Wekken AJ, Groen HJM, et al. A

- nationwide study on the impact of routine testing for EGFR mutations in advanced NSCLC reveals distinct survival patterns based on EGFR mutation subclasses. *Cancers (Basel)*. 2021;**13**:3641. <https://doi.org/10.3390/cancers13143641>
- 20 Van Sanden S, Murton M, Bobrowska A, Rahhali N, Sermon J, Rodrigues B, et al. Prevalence of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer in Europe: a pragmatic literature review and meta-analysis. *Target Oncol*. 2022;**17**:153–66. <https://doi.org/10.1007/s11523-022-00868-z>
 - 21 He C, Wei C, Wen J, Chen S, Chen L, Wu Y, et al. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients. *J Cancer Res Clin Oncol*. 2022;**148**:321–30. <https://doi.org/10.1007/s00432-021-03818-w>
 - 22 Ou S, Hong J, Lin H, Vincent S, Churchill E, Soeda J, et al. MA14.01 distribution and detectability of EGFR exon 20 insertion variants in non-small cell lung cancer. *J Thorac Oncol*. 2021;**16**:S928–9. <https://doi.org/10.1016/j.jtho.2021.08.182>
 - 23 Pennell NA, Mutebi A, Zhou Z-Y, Ricculi ML, Tang W, Wang H, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model. *JCO Precis Oncol*. 2019;**3**:1–9. <https://doi.org/10.1200/po.18.00356>
 - 24 Remon J, Dienstmann R. Precision oncology: separating the wheat from the chaff. *ESMO Open*. 2018;**3**:e000446. <https://doi.org/10.1136/esmoopen-2018-000446>
 - 25 Ionescu F, Zhang J, Wang L. Clinical applications of liquid biopsy in prostate cancer: from screening to predictive biomarker. *Cancers (Basel)*. 2022;**14**:1728. <https://doi.org/10.3390/cancers14071728>

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. EGFR ex20ins variants detected by PCR screening kits.

Table S2. EGFR ex20ins variants identified in patients from the GENIE dataset ($N = 180$).

Table S3. EGFR ex20ins variants identified in patients from the FoundationInsights dataset ($N = 627$).

Table S4. EGFR ex20ins variants identified in patients from the GuardantINFORM dataset ($N = 627$).